TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed deleterious or suspected deleterious germline BRCA1 or BRCA2 mutation~2. Locally advanced or metastatic breast cancer despite standard therapy and the following:~   1. Histologically or cytologically confirmed HER2(-) breast cancer (TNBC or estrogen receptor-positive and/or PR+)~  2. ≤ 2 prior lines of chemotherapy in advanced or metastatic setting~  3. Prior platinum therapy allowed as long as no disease progression while on treatment, or if given in neoadjuvant/adjuvant setting with ≥ 6 months from last platinum to relapse~  4. Prior therapy with an anthracycline and/or a taxane in neoadjuvant/adjuvant or metastatic setting~  5. Archival tumor tissues will be collected from all patients, if available~  6. For HR(+)/HER2(-) breast cancer only: patients must have received and progressed on at least one endocrine therapy either in adjuvant or metastatic setting, or have disease that the treating physician believes to be inappropriate for endocrine therapy~3. Measurable disease as defined per RECIST, version 1.1~4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1~5. Adequate hematologic and organ function~Exclusion Criteria:~1. Unresolved acute effects of prior therapy of ≥ Grade 2~2. Prior treatment with a poly\[ADP-ribose\] polymerase (PARP) inhibitor~3. Chemotherapy, radiotherapy, biologic therapy, immunotherapy, investigational agent, anticancer Chinese medicine, or anticancer herbal remedies ≤ 14 days (or ≤ 5 half lives, if applicable, whichever is shorter) prior to Day 1 of Cycle 1~4. Major surgical procedure, open biopsy, or significant traumatic injury ≤ 14 days prior to Day 1 of Cycle 1, or anticipation of need for major surgical procedure during the course of the study~5. Diagnosis of myelodysplastic syndrome (MDS)~6. Other diagnosis of malignancy~7. Untreated and/or active brain metastases.~8. Active infection requiring systemic treatment, active viral hepatitis, or active tuberculosis~9. Clinically significant cardiovascular disease~10. Pregnancy or nursing~11. Known history of intolerance to the excipients of the BGB-290 capsule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Triple-negative breast cancer (TNBC) (Type: EXPERIMENTAL): Locally advanced or metastatic TNBC
- Cohort 2: HR(+)/HER2(-) breast cancer (Type: EXPERIMENTAL): Locally advanced or metastatic Hormone receptor-positive(HR+) human epidermal growth factor receptor2 Negative(HER2-) breast cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* locally advanced stage III or IV squamous cell carcinoma of the larynx, oropharynx, or hypopharynx~* ≥18 years old~* absolute neutrophil count ≥1,500/µL, platelets ≥100,000/µL~* serum bilirubin \<2.0 mg/dL~* creatinine \<1.5 mg/dL~* serum transaminase levels less than twice the upper limit of normal~Exclusion Criteria:~* received previous chemotherapy~* another malignancy~* current or history of distant metastasis~* history of clinically significant cardiac disease within 6 months~* active serious infection~* nasopharyngeal carcinoma~* psychiatric illness that would preclude obtaining informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1, induction chemotherapy (Type: EXPERIMENTAL): Cisplatin and 5-FU is the standard treatment for patients with head and neck cancer. Recently,docetaxel was used into CF, and it showed the prolongation of survival. Oral 5-FU showed similar or enhanced response rate, safety than intravenous 5-FU. S-1 showed promising preliminary result in combination with cisplatin in head and neck cancer. In patients with gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid, 60mg/m2 (D1) and 60mg/m2 (D1), respectively. And weekly docetaxel can reduce adverse events compared to 3 week regimen. The aim of this study was to evaluate the efficacy and safety of weekly docetaxel, cisplatin and S-1 combination chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3437943 in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Have Type 2 Diabetes (T2D)~* Have an HbA1c value at screening of ≥7.0% and ≤10.5% and treated with diet and exercise alone or with a stable dose of metformin (either immediate release or extended release, 1000 milligram (mg)/day and not more than the locally approved dose) for at least 3 months prior to screening.~Exclusion Criteria:~* Have type 1 diabetes mellitus (T1DM)~* Have ketoacidosis~* Have retinopathy, maculopathy~* Have history of pancreatitis~* Have obesity induced by other endocrine disorders~* Have uncontrolled hypertension~* Have acute or chronic hepatitis~* Have chronic kidney disease~* Have an autoimmune abnormality for example, lupus or rheumatoid arthritis~* Have an active or untreated malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 0.5 milligrams (mg) LY3437943 (Type: EXPERIMENTAL): Participants received 0.5 mg LY3437943 administered as SC (subcutaneous) injection once weekly (QW).
- 4 mg LY3437943 (2 mg) (Type: EXPERIMENTAL): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
- 4 mg LY3437943 (4 mg) (Type: EXPERIMENTAL): Participants received 4 mg LY3437943 administered as SC injection QW.
- 8 mg LY3437943 (2 mg) (Type: EXPERIMENTAL): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
- 8 mg LY3437943 (4 mg) (Type: EXPERIMENTAL): Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.
- 12 mg LY3437943 (2 mg) (Type: EXPERIMENTAL): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as a SC injection QW.
- 1.5 mg Dulaglutide (Type: ACTIVE_COMPARATOR): Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered as SC injection QW.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Major Inclusion Criteria:~* Provision of written informed consent prior to any study-specific procedure~* Fasting LDL-C between 130 and 220 mg/dL following wash-out of all lipid regulating medications and supplements~* Fasting triglyceride \<400 mg/dL following wash-out of all lipid regulating medications and supplements~* BMI between 18 and 35 mg/kg2~Major Exclusion Criteria:~* Clinically significant cardiovascular disease, diabetes or uncontrolled hypertension~* Females of child bearing potential (i.e., females who are not surgically sterile or post-menopausal)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 120 mg (Group 1) (Type: EXPERIMENTAL): Subjects with hypercholesterolemia and normal triglycerides
- ETC-1002 80 mg (Group 2) (Type: EXPERIMENTAL): Subjects with hypercholesterolemia and normal triglycerides
- ETC-1002 40 mg (Group 3) (Type: EXPERIMENTAL): Subjects with hypercholesterolemia and normal triglycerides
- Placebo (Group 4) (Type: EXPERIMENTAL): Subjects with hypercholesterolemia and normal triglycerides
- ETC-1002 120 mg (Group 5) (Type: EXPERIMENTAL): Subjects with hypercholesterolemia and elevated triglycerides
- ETC-1002 80 mg (Group 6) (Type: EXPERIMENTAL): Subjects with hypercholesterolemia and elevated triglycerides
- ETC-1002 40 mg (Group 7) (Type: EXPERIMENTAL): Subjects with hypercholesterolemia and elevated triglycerides
- Placebo (Group 8) (Type: EXPERIMENTAL): Subjects with hypercholesterolemia and elevated triglycerides

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Negative clinical history for varicella, herpes zoster, measles, mumps, and rubella~Exclusion Criteria:~* Received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study~* Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity~* Received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to receive them during the course of the study~* History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg proteins, chicken proteins, or any component of VARIVAX® or M-M-R II®~* Has any blood dyscrasias, leukemia, lymphoma, or other malignant neoplasm affecting the bone marrow or lymphatic systems~* Received salicylates within 14 days prior to study vaccination~* Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior to study vaccination~* Received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to study vaccination~* History of seizure disorder, including febrile seizure~* Fever illness (\>=102.2 °F \[39.0 °C\] within 72 hours prior to study vaccination~* History of thrombocytopenia~* Born to a human immunodeficiency virus (HIV)-infected mother~* Has a diagnosis of active untreated tuberculosis~* Participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- VARIVAX® PE34 Process + Measles, Mumps, Rubella (M-M-R) II® (Type: EXPERIMENTAL): VARIVAX® Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
- VARIVAX® 2016 Commercial Process + M-M-R II® (Type: ACTIVE_COMPARATOR): VARIVAX® 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Helicobacter Eradication Relief of Dyspeptic Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with more than 18 years~* Functional dyspepsia accordingly Rome III criteria~* Helicobacter pylori infection by two diagnostic tests~Exclusion Criteria:~* No concordance with informed consent~* Pregnant woman or breast feeding or no trust anticonceptional method~* Structural gastrointestinal abnormalities except gastritis, duodenitis or hiatal hernia~* Previous treatment for Helicobacter pylori infection~* Previous surgery on esophagus, stomach or duodenum~* Hypersensitivity to the drugs in study~* Proton pump inhibitor use in the previous 15 days~* H2-antagonists use in the previous 07 days~* Antibiotics use in the previous 30 days~* Patients unable to answer the study questionnaires~* Alcohol abuse~* Drug use~* Serious comorbidities~* Biliary colic~* Irritable bowel syndrome~* Gastroesophageal Reflux Disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Amoxicillin 1000 mg BID, clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
- 2 (Type: PLACEBO_COMPARATOR): Placebo of Amoxicillin 1000 mg BID, placebo of clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* FLT3-ITD Positive AML~* Allo-HSCT Recipients~Exclusion Criteria:~* cardiac dysfunction (particularly congestive heart failure)~* hepatic abnormalities (bilirubin ≥ 3 mg/dL, aminotransferase\> 2 times the upper limit of normal)~* renal dysfunction (creatinine clearance rate \< 30 mL/min)~* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)~* Patients with any conditions not suitable for the trial (investigators' decision)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Sorafenib group (Type: EXPERIMENTAL): Sorafenib will be used from day 30 to 180 post-transplantation.
- non-Sorafenib group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent before enrollment and any study-specific procedures. Patients deemed incapable of providing written consent will not be enrolled in this study; outpatient status~Exclusion Criteria:~* More than 8 mood episodes in the past year from screen (visit 1);~* A current Axis I disorder other than bipolar disorder within 6 months of screening;~* patients with clinically significant abnormal laboratory findings in the investigator's judgment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 60 and older~* Current Major Depressive Disorder (MDD)~* Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length~* Patient Health Questionnaire-9 (PHQ-9) score of 10 or higher~Exclusion Criteria:~* Inability to provide informed consent~* Dementia~* Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms~* High risk for suicide and unable to be managed safely in the clinical trial~* Contraindication to proposed study medications, as determined by study physician including history of intolerance or non-response to proposed medications.~* Non-correctable, clinically significant sensory impairment interfering with participation~* Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management.~* Moderate to severe substance or alcohol use disorder

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aripiprazole Augmentation (Type: EXPERIMENTAL): Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
- Bupropion Augmentation (Type: EXPERIMENTAL): Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
- Switch to Bupropion (Type: EXPERIMENTAL): Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
- Lithium Augmentation (Type: EXPERIMENTAL): Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
- Switch to Nortriptyline (Type: EXPERIMENTAL): Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Irritable Bowel Syndrome (IBS) (ROME III criteria): subtype with diarrhea or mixed form~* age 18-65 years~Exclusion Criteria:~* IBS subtype with constipation~* medication: antidepressants or H1-receptor antagonists~* pregnancy, breast feeding~* co-morbidity: severe kidney- and/or liver disease or other gastrointestinal diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ebastine (Type: ACTIVE_COMPARATOR): Ebastine
- placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years old or above~* Diagnosed as chronic urticaria based on The EAACI/GA(2)LEN/EDF/WAO Guideline~* Literate in Thai language and can complete the questionnaire by themselves~Exclusion Criteria:~* Have other active skin diseases~* Have a psychiatric problem~* Cannot understand the questionnaire by themselves.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CU-Q2oL (Type: None): * Evaluation by the Urticaria Activity Score (UAS7)~* Fill the DLQI and CU-Q2oL questionnaire

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients that will be included in the study have cirrhosis as diagnosed by clinical, biochemical, and ultrasound findings, with HRS type 1, the absence of bacterial infections; however, patients with bacterial infections could be included in the study if renal failure persisted after infection resolution by clinical, laboratory indices up to 48 hours.~Exclusion Criteria:~* Patients will be excluded if there are advanced cardiovascular diseases due to poor prognosis or any extrahepatic disease that could affect the short-term prognosis, the presence of advanced hepatocellular carcinoma or presence of contraindication to norepinephrine as hypotension due to blood volume deficits except emergency measure, mesenteric or peripheral vascular thrombosis unless there is life-saving procedure, profound hypoxia or hypercarbia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- norepinephrine (Type: ACTIVE_COMPARATOR): norepinephrine continuous intravenous infusion in a dose of 0.05-0.3ug/Kg/min. average7-10 days to keep mean arterial pressure ≥ 80-100mmHg \& continued either until HRS reversal or for maximum 10 days.
- midodrine & octreotide (Type: ACTIVE_COMPARATOR): midodrine 5mg three times/day orally \& can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous \& if needed increased to 200ug/6hS.C. for 7-10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete